Synapse - Works

Results (62)

A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant

Meeting Abstract

Foley, N. C.; Russler-Germain, D.; Watkins, M.; Jacobsen, E. D.; Moskowitz, A. J.; Cashen, A. F.; Fehniger, T. A.; Kahl, B. S.; Ghobadi, A.; Reagan, B.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant

Meeting Abstract

Stuver, R.; Mazloom, A.; Ganesan, N.; Horwitz, S. M.; Moskowitz, A. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Alliance A059102: A randomized phase II US intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Geyer, S. M.; Barta, S. K.; Amengual, J. E.; Dockter, T.; Wright, C.; Dinner, S.; Hsi, E. D.; Bartlett, N. L.; Horwitz, S. M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma

Meeting Abstract

Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma

Journal Article

Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice

Meeting Abstract

Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)

Meeting Abstract

Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Symptomatic delayed seromas vs incidental findings on MR, and likelihood of BIA-ALCL in women with textured implants

Meeting Abstract

Ghione, P.; Sutton, E. J.; Hu, Q.; Galasso, N.; Ganesan, N.; Tyagi, N.; Martinez, D. F.; Dogan, A.; Morris, E. A.; Horwitz, S. M.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab

Meeting Abstract

Ghione, P.; Joffe, E.; De Paola, N.; Mainardi, T.; Noor, S. J.; Bobillo, S.; Myskowski, P. L.; Palomba, M. L.; Moskowitz, A. J.; Mato, A. R.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save